HUTCHMED's ORPATHYS® receives full approval in China for lung cancer treatment with MET alterations.

From GlobeNewswire: 2025-01-13 23:00:00

HUTCHMED’s ORPATHYS® receives approval from NMPA in China for the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, including both treatment-naïve and previously treated patients. Phase IIIb trial data showed an ORR of 62.1% and 39.2% in treatment-naïve and previously treated patients, respectively, with tolerable safety profile. ORPATHYS® is the first selective MET inhibitor approved in China, offering a new treatment option for patients with this challenging form of lung cancer. AstraZeneca, HUTCHMED’s partner, is proud to provide this transformative therapy to patients in China.

MET aberrations play a crucial role in the progression of NSCLC, with approximately 2-3% of patients having MET exon 14 skipping alterations. ORPATHYS® (savolitinib) is a highly selective MET TKI that has shown clinical activity in advanced solid tumors, representing a potential targeted therapy for patients with MET-driven cancers. AstraZeneca and HUTCHMED’s partnership aims to address the unmet medical needs of patients with NSCLC, offering new possibilities for treating MET-altered and amplified cancers. The approval of ORPATHYS® marks a significant advancement in personalized treatment for patients with advanced NSCLC with MET exon 14 skipping alterations, bringing hope to those in need of targeted therapy.



Read more at GlobeNewswire: HUTCHMED Announces NMPA Full Approval for